NAD+

Central redox cofactor and signalling node for sirtuins, PARPs and mitochondrial metabolism, targeted indirectly via IV NAD+, NMN, NR and related precursors in research settings.

Evidence: Strong Biochemistry + Mixed Human Function: Redox, Sirtuins & Mitochondria Class: Dinucleotide cofactor axis

Explore calculators for this axis

Use the Peptide Research Tools to simulate NAD+-axis interventions (IV NAD+, NMN, NR) with mg/kg and infusion-duration models. All values are placeholders and must be aligned with your own research protocol.

Open NAD+ axis in calculators →

Research frame & potential applications

NAD+ is an essential cofactor in redox reactions, substrate for sirtuins and PARPs, and a central regulator of mitochondrial metabolism, DNA repair and cellular stress responses. Research focuses on how boosting NAD+ pools through precursors or IV administration influences metabolic health, neurodegeneration, muscle function and aging trajectories.

Research areas & putative benefits

How NAD+ replenishment strategies are explored in experimental and clinical contexts.

Metabolic health: insulin resistance, fatty-liver models, exercise capacity and mitochondrial function in muscle and liver.
Neurodegeneration and CNS aging: axonal integrity, neuroinflammation, cognitive decline and circadian regulation.
Cellular senescence and DNA repair: PARP activity, double-strand break repair and stress-resilience pathways.
Fatigue and performance: subjective fatigue, recovery from intense exertion and autonomic balance in small human studies.

Mechanism stack

From redox cofactor to longevity and stress signalling hub.

Core biochemistry

Redox & mitochondrial metabolism

NAD+/NADH couples support glycolysis, TCA cycle and oxidative phosphorylation, directly controlling ATP production and mitochondrial redox state.

Sirtuins

NAD+-dependent deacetylases

Sirtuins consume NAD+ to deacetylate metabolic, mitochondrial and chromatin proteins, influencing stress resistance, mitochondrial biogenesis and aspects of longevity biology.

DNA repair

PARPs & genome maintenance

PARP enzymes use NAD+ to poly-ADP-ribosylate proteins at DNA damage sites, recruiting repair factors; chronic over-activation can deplete NAD+ and ATP under severe stress.

NAD+ pools

Salvage pathways & precursors

Precursor molecules (NR, NMN, nicotinamide, tryptophan) feed into NAD+ salvage and de novo pathways, while IV NAD+ may transiently spike circulating and tissue pools in some compartments.

Evidence snapshot

Selected findings from NAD+-boosting strategies and translational work.

Intervention / context	Observation	Notes
NR / NMN supplementation in rodents Preclinical	Increases tissue NAD+ levels, improves mitochondrial function, insulin sensitivity and some healthspan markers in multiple aging and metabolic models.	Foundational for the NAD+-boosting longevity narrative.
Oral precursors in humans Clinical	Raise blood NAD+ metabolites; mixed results on insulin sensitivity, lipid profiles, physical performance and subjective outcomes across small trials.	Heterogeneous endpoints and dosing schemes limit firm clinical conclusions.
IV NAD+ protocols Translational	Used in pilot settings to explore acute effects on withdrawal syndromes, fatigue and cognitive performance; controlled data remain sparse.	Rapid infusion can be poorly tolerated unless slowed substantially.
NAD+ decline with age Human biology	Multiple tissues show declining NAD+ levels with age, correlating with mitochondrial dysfunction and increased inflammation.	Provides rationale for considering NAD+-axis interventions in aging research.

Risk frame & unknowns

Caveats around NAD+-boosting and longevity claims.

Important research caveats

Long-term high-dose NAD+ precursor or IV NAD+ exposure has not been extensively studied for cancer, cardiovascular or neurological outcomes.
Boosting NAD+ may support both healthy and malignant cells; theoretical oncogenic concerns remain under investigation.
Human trials often use small samples, short durations and surrogate endpoints rather than hard clinical outcomes.
Off-label IV protocols vary widely in dose and infusion rate, with limited standardisation or regulatory oversight in many regions.

This dossier summarizes mechanistic, preclinical and clinical findings on NAD+ and its precursors for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.